Value What Matters!
The fair value specialist for innovative Life Sciences — under scrutiny.
Accounting
Legal
Tax
A different playbook, applying deep life sciences context & valuation expertise to accounting, legal and tax purposes — where unfamiliar risk, growth and uncertainty often push frameworks to their limits.
Why we are made for this Our take on Life Sciences
In innovative Life Sciences, the operating reality is often unfamiliar to accounting, legal and tax frameworks. Risk is intrinsic, assets are incomplete, largely intangible, and value evolves through event-driven transitions. This regularly creates tension — not because something is wrong, but because the context itself is exceptional.
Applying standards and formulas mechanically is rarely sufficient. Fair value in Life Sciences requires contextual correctness: understanding how scientific risk, development pathways, business model, timing, governance and market behaviour interact — and which drivers truly matter for the valuation’s specific purpose.
Being a specialist in this field requires,
- mathematical depth,
- operational understanding from science to governance,
- clear reading of market behaviour,
applied together. Not in silos.
We address one core question: Is this value right for its purpose, right for its context, and right under scrutiny?
Addressing the core points of tension
Context-sharp
We start from operational reality. Science, development pathways, contracts, partners, governance and stage-specific risks are assessed together, not in silos.
Complexity-aware
We strip complexity down to what matters. Assumptions, benchmarks and modelling are limited to what is decision-critical for the specific accounting, tax or legal purpose.
Inconsistencies detected early
We detect misalignments early — between assumptions, incentives, timelines and outcomes — and address them before scrutiny does.
When we are engaged
We are engaged in a broad range of accounting, legal and tax situations where fair value is material and sensitive. This includes third-party fairness opinions, complex fair value matters including under IFRS 2, 9, 13, 15, US GAAP, HGB, Swiss GAAP, valuation for transfer pricing and IP transactions, as well as situations involving latent taxation of value.
We are frequently asked to model, report, review and sanity-check valuations — particularly when assets, structures or stages fall outside standard practice and require specialist judgment, often across jurisdictions.
We are also engaged when fair value is contested, including litigation and dispute contexts, where our ability to reconstruct context, trace assumptions, and identify inconsistencies is critical.
Transfer price
Innovative assets changing ownership or jurisdiction
Complex contract
Accounting of structured financing and partnering arrangements (CLA, warrants, structured debt, option deals, contingent payments)
IP valuation
Value of patents, inventor interests and ownership stakes
Incentives
Non-standard structures, adapted benchmarks, latent taxation and long-term liability projections
Who we support
We support listed and private innovative biotech, medtech and health tech companies, as well as investment structures such as funds and family offices, across Europe and the US.
We are often engaged in:
- cross-border situations — notably when US investors are involved in European assets
- early or transitional stages where fair value needs arise before companies are equipped
- transition to public markets and heightened scrutiny
Who calls us
We are most often engaged by CFOs, heads of finance, funds managers and family offices and frequently recommended by highly experienced lawyers, accountants and IFRS experts who recognize the underlying complexity of Life Sciences valuation.
These are professionals with long exposure to edge cases, who know when standard approaches — or life sciences-naïve ones — no longer suffice and when specialized, context-aware judgment is required.
What this delivers
Beyond resolving the immediate valuation question, our work typically elevates understanding at company level. Our models and analyses often serve dual purposes.
By seeing deeper into innovative assets, financing and partnering contracts, their drivers and constraints, we help CFOs gain clarity, confidence and control — strengthening governance, negotiations, business development and strategic decision-making well beyond the initial scope.
Continue reading